Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet

Stopped Lack of patients who are eligible for inclusion: less patients on treatment and not using epclusa.

Conditions

• HCV

Interventions

• DRUG: sofosbuvir/velpatasvir tablet
• DRUG: sofosbuvir/velpatasvir crushed

Sponsor

Radboud University Medical Center